Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Iovance Biotherapeutics to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Iovance Biotherapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Iovance Biotherapeutics | 1 | 3 | 9 | 1 | 2.71 |
| Iovance Biotherapeutics Competitors | 9923 | 15313 | 45670 | 1602 | 2.54 |
Iovance Biotherapeutics presently has a consensus price target of $13.80, suggesting a potential upside of 77.84%. As a group, “Biotechnology” companies have a potential upside of 126.40%. Given Iovance Biotherapeutics’ rivals higher probable upside, analysts clearly believe Iovance Biotherapeutics has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Iovance Biotherapeutics and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Iovance Biotherapeutics | $263.50 million | -$390.98 million | -14.64 |
| Iovance Biotherapeutics Competitors | $755.35 million | $11.71 million | -18.77 |
Iovance Biotherapeutics’ rivals have higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Iovance Biotherapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Iovance Biotherapeutics | -58.20% | -29.71% | -23.55% |
| Iovance Biotherapeutics Competitors | -12,224.09% | -202.33% | -31.23% |
Risk and Volatility
Iovance Biotherapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics’ rivals have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Institutional & Insider Ownership
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Iovance Biotherapeutics beats its rivals on 9 of the 13 factors compared.
About Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
